AsciepiX Therapeutics Inc., based in Baltimore, Maryland, has announced that the first patient has been dosed in the Phase 1/2a “CONGO” clinical trial to evaluate… Read More »AsclepiX Therapeutics Inc. has reported the first dose of a novel peptide treatment in Phase 1/2a for Diabetic Macular Edema (DME)
The EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) has reported that safety-related aspects of Eylea (aflibercept) may lead to “a higher-than-expected proportion of cases of increased… Read More »The EMA has advised that pre-filled syringes with aflibercept can lead to IOP issues if not correctly handled.
Researchers at the Department of Ophthalmology, Ludwig-Maximilians-University, Munich, have reported results on novel engineered viral vectors aimed to efficiently target photoreceptors. The research used a… Read More »Novel engineered vectors (recombinant adeno-associated virus [vAAV]) may provide efficient targeting for photoreceptors avoiding risks of collateral damage.
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 1st, 2021 edition of EURETINA’s web-based digital magazine,… Read More »April 1st, 2021: “EURETINA-Brief”© Issue No. 232
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the December 18th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »December 18th, 2019: “EURETINA-Brief”© Issue No. 204
Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Paperback ISBN: 9780128162224 eBook ISBN: 9780128167274; Pages 383,… Read More »Genetics and Genomics of Eye Disease, 1st Edition – Advancing to Precision Medicine (Elsevier) Editors: Xiaoyi Gao Ph.D.
Researchers at the Sydney Institute of Vision Science, in New South Wales, Australia report that good long-term efficacy of anti-VEGF therapy over 5 years provides… Read More »Five-year outcomes of retinal vein occlusion provide long term data for anti-VEGF treatments on real-world data
by Dr. Gearóid Tuohy Dear EURETINA Members, A very warm welcome to the April 16th, 2019 edition of EURETINA’s web-based digital magazine, “EURETINA… Read More »April 16th, 2019: “EURETINA-Brief” Issue No. 190
Editas Medicine, Inc. (NASDAQ: EDIT), based in Dublin, Ireland and Cambridge, Massachusetts, and Allergan plc (NYSE: AGN), also headquartered in Dublin, Ireland have announced the… Read More »Editas Medicine Inc. (NASDAQ:EDIT), and Allergan plc (NYSE:AGN), progress option rights to develop CRISPR technology for treatment of LCA 10
EURETINA, through a collaboration with Fight for Sight, have announced a dedicated Research Call to support clinical research in the field of sub-macular haemorrhage (SMH),… Read More »***EURETINA / Fight for Sight launch Sub-Macular Haemorrhage (SMH) Clinical Research Call***